Immune-based, multifaceted inactivation of pathogenic T lymphocytes in treating autoimmune diseases

Abstract

Immunotherapeutic treatment of autoimmune diseases should aim to inactivate autoaggressive memory T-cells and restore immune tolerance. It is envisaged that three approaches could be used to achieve this goal: stimulation of anti-idiotypic immune responses by vaccination with pathogenic T-cells; administration of suboptimal doses of antibodies (Abs) against two or more surface T-cell markers to provide selective Ab-mediated destruction of activated pathogenic memory T-cells; and induction of oral immune tolerance. The proposal entails the use of T-cell vaccination (TCV) or Ab-based therapy as an initial approach to reduce autoantigenic T-cell sensitization. Subsequently, the implementation of oral immunotherapy (OIT) is recommended to reinstate a consistent immune tolerance.

Keywords

Autoimmune disease / memory T-cell / T-cell vaccination / therapeutic antibody / oral immunotherapy

References

[1] Seledtsov VI, von Delwig AA. Immune memory limits human longevity: the role of memory СD4+ T cells in age-related immune abnormalities. Expert Rev Vaccines. 2020; 19: 209-15.

[2] Lutterotti A, Martin R. Antigen-specific tolerization approaches in multiple sclerosis. Expert Opin Investig Drugs. 2014; 23: 9-20.

[3] Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol. 2000; 164: 4011-7.

[4] Vandenbark AA, Abulafia-Lapid R. Autologous T-cell vaccination for multiple sclerosis: a perspective on progress. BioDrugs. 2008; 22: 265-73.

[5] Seledtsova GV, Ivanova IP, Shishkov AA, Seledtsov VI. Immune responses to polyclonal T-cell vaccination in patients with progressive multiple sclerosis. J Immunotoxicol. 2016; 13: 879-84.

[6] VanderBorght A, Geusens P, Raus J, Stinissen P. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum. 2001; 31: 160-75.

[7] Ivanova I, Seledtsova G, Mamaev S, Shishkov A, Seledtsov V. Immune responses induced by T-cell vaccination in patients with rheumatoid arthritis. Hum Vaccin Immunother. 2014; 10: 1221-7.

[8] Hong J, Zang YC, Tejada-Simon MV, Li S, Rivera VM, Killian J, et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol. 2000; 165: 6858-64.

[9] Seledtsov VI, Seledtsova GV. Total threshold cytotoxicity of therapeutic antibodies for selective destruction of pathogenic memory T cells: implications for immunotherapy of autoimmune and allergenic disorders. Expert Rev Clin Immunol. 2019; 15: 701-6.

[10] Seledtsov VI, Seledtsova GV. Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article. Oncotarget. 2018; 9: 35790-4.

[11] Pinheiro-Rosa N, Torres L, Oliveira MA, Andrade-Oliveira MF, Guimarães MAF, Coelho MM, et al. Oral tolerance as antigen-specific immunotherapy. Immunother Adv. 2021; 1: ltab017.

[12] Ghobadinezhad F, Ebrahimi N, Mozaffari F, Moradi N, Beiranvand S, Pournazari M, et al. The emerging role of regulatory cell-based therapy in autoimmune disease. Front Immunol. 2022; 13: 1075813.

[13] Commins SP. Mechanisms of oral tolerance. Pediatr Clin North Am. 2015; 62: 1523-9.

[14] Akagbosu B, Tayyebi Z, Shibu G, Paucar Iza YA, Deep D, Parisotto YF, et al. Novel antigen-presenting cell imparts T_reg-dependent tolerance to gut microbiota . Nature. 2022; 610: 752-60.

[15] Schmidt SV, Nino-Castro AC, Schultze JL. Regulatory dendritic cells: there is more than just immune activation. Front Immunol. 2012; 3: 274.

[16] Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes . J Exp Med. 2004; 199: 1455-65.

[17] Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006; 13: 143-57.

[18] Yoshida T, Hachimura S, Kaminogawa S. The oral administration of low-dose antigen induces activation followed by tolerization, while high-dose antigen induces tolerance without activation. Clin Immunol Immunopathol. 1997; 82: 207-15.

[19] Dubois B, Chapat L, Goubier A, Papiernik M, Nicolas JF, Kaiserlian D. Innate CD4⁺CD25⁺ regulatory T cells are required for oral tolerance and inhibition of CD8⁺ T cells mediating skin inflammation . Blood. 2003; 102: 3295-301.

[20] Faria AM, Maron R, Ficker SM, Slavin AJ, Spahn T, Weiner HL. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-β/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J Autoimmun. 2003; 20: 135-45.

[21] Oliveira RP, Santiago AF, Ficker SM, Gomes-Santos AC, Faria AMC. Antigen administration by continuous feeding enhances oral tolerance and leads to long-lasting effects. J Immunol Methods. 2015; 421: 36-43.

[22] Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986; 83: 7443-6.

[23] Bitar DM, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol. 1988; 112: 364-70.

[24] Jacobsen LM, Schatz DA. Insulin immunotherapy for pretype 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2021; 28: 390-6.

[25] Conde AA, Stransky B, Faria AM, Vaz NM. Interruption of recently induced immune responses by oral administration of antigen. Braz J Med Biol Res. 1998; 31: 377-80.